Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Tecan successfully completes the acquisition of SPEware Corporation

Tecan Group AG
Posted on: 03 Oct 16

Männedorf, Switzerland, October 3, 2016 - The Tecan Group (SIX Swiss Exchange: TECN) announced today that it has successfully completed the acquisition of SPEware Corporation (SPEware) on September 30, 2016. On August 31, 2016, Tecan announced the acquisition of SPEware, a leading provider for mass spectrometry sample preparation solutions based in Baldwin Park, California (USA), to further expand Tecan's dedicated solutions offering into a new market segment. From October 1, 2016, SPEware will be included in the consolidated financial statements of the Tecan Group as a part of the Life Sciences Business segment.

Additional information can be found on the SPEware webpage:

About Tecan
Tecan ( ) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2015, Tecan generated sales of CHF 440 million (USD 459 million; EUR 411 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

For further information:

Tecan Group
Martin Braendle
Vice President, Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89

Press Release

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Tecan Group AG via GlobeNewswire

Last updated on: 04/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.